Atara Biotherapeutics (ATRA) Return on Sales (2021 - 2026)

Atara Biotherapeutics' Return on Sales history runs 6 years deep, the most recent figure standing at 0.08% for Q1 2026.

• Quarterly Return on Sales fell 8.0% year-over-year to 0.08% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 0.0% (changed 0.0% YoY) and the FY2025 annual result came in at 0.0%, up 1.0% from the prior year.
• Return on Sales was 0.08% for Q1 2026 at Atara Biotherapeutics, down from 0.02% in the prior quarter.
• Across five years, Return on Sales topped out at 0.2% in Q4 2023 and bottomed at 4.34% in Q2 2023.
• A 5-year average of 0.37% and a median of 0.01% in 2025 frame the typical range for Return on Sales.
• Annual changes were most pronounced in 2023 — Return on Sales sank 434 bps — and 2024, when it surged 433 bps.
• Atara Biotherapeutics' Return on Sales stood at 0.42% in 2022, then jumped by 148 bps to 0.2% in 2023, then slumped by 102 bps to 0.0% in 2024, then sank by 448 bps to 0.02% in 2025, then sank by 278 bps to 0.08% in 2026.
• Business Quant data shows ATRA's Return on Sales at 0.08% in Q1 2026, 0.02% in Q4 2025, and 0.01% in Q3 2025.